CA2825218A1 - Colon cancer gene expression signatures and methods of use - Google Patents

Colon cancer gene expression signatures and methods of use Download PDF

Info

Publication number
CA2825218A1
CA2825218A1 CA2825218A CA2825218A CA2825218A1 CA 2825218 A1 CA2825218 A1 CA 2825218A1 CA 2825218 A CA2825218 A CA 2825218A CA 2825218 A CA2825218 A CA 2825218A CA 2825218 A1 CA2825218 A1 CA 2825218A1
Authority
CA
Canada
Prior art keywords
colon cancer
transcripts
nucleic acid
sample
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2825218A
Other languages
English (en)
French (fr)
Inventor
Denis Paul Harkin
Vitali Proutski
Julie BLACK
Peter Kerr
Richard Kennedy
Andreas Winter
Timothy Davison
Max Bylesjo
Vadim FARZTDINOV
Claire WILSON
Robert James Holt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Diagnostics Ltd
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of CA2825218A1 publication Critical patent/CA2825218A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2825218A 2011-01-25 2012-01-25 Colon cancer gene expression signatures and methods of use Abandoned CA2825218A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161435922P 2011-01-25 2011-01-25
US61/435,922 2011-01-25
PCT/US2012/022594 WO2012103250A2 (en) 2011-01-25 2012-01-25 Colon cancer gene expression signatures and methods of use

Publications (1)

Publication Number Publication Date
CA2825218A1 true CA2825218A1 (en) 2012-08-02

Family

ID=46581385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2825218A Abandoned CA2825218A1 (en) 2011-01-25 2012-01-25 Colon cancer gene expression signatures and methods of use

Country Status (14)

Country Link
US (1) US10196691B2 (cg-RX-API-DMAC7.html)
EP (1) EP2668296B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014509189A (cg-RX-API-DMAC7.html)
KR (1) KR20140006898A (cg-RX-API-DMAC7.html)
CN (1) CN103403543B9 (cg-RX-API-DMAC7.html)
AU (1) AU2012209074A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013018924A2 (cg-RX-API-DMAC7.html)
CA (1) CA2825218A1 (cg-RX-API-DMAC7.html)
EA (1) EA201391074A1 (cg-RX-API-DMAC7.html)
IL (1) IL227643A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013008367A (cg-RX-API-DMAC7.html)
SG (1) SG192108A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012103250A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201305024B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
RS54482B1 (sr) 2010-04-05 2016-06-30 Prognosys Biosciences, Inc. Biološka testiranja sa prostornim kodiranjem
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
US20130074201A1 (en) * 2011-09-16 2013-03-21 The Johns Hopkins University Cancer-specific genetic rearrangements
EP3901280B1 (en) * 2012-10-17 2025-03-12 10x Genomics Sweden AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
LT3013983T (lt) 2013-06-25 2023-05-10 Prognosys Biosciences, Inc. Erdviniai koduoti biologiniai tyrimai, naudojant mikrofluidinį įrenginį
US9652722B1 (en) * 2013-12-05 2017-05-16 The Mathworks, Inc. Methods and systems for robust supervised machine learning
CA2939697A1 (en) * 2014-02-17 2015-08-20 Ventana Medical Systems, Inc. G-alpha, interacting vesicle associated protein (giv) as a predictive marker in stage ii colorectal cancer
JP6608424B2 (ja) * 2014-04-10 2019-11-20 バイオ−マルケア テクノロジーズ リミテッド 前癌性結腸直腸ポリープおよび結腸直腸癌を特定するための方法およびキット
HK1250245A1 (zh) 2015-04-10 2018-12-07 Spatial Transcriptomics Ab 生物样本的空间区别、多重核酸分析
CN108020672A (zh) * 2016-11-03 2018-05-11 中国医学科学院基础医学研究所 检测rhbdd1蛋白的elisa方法及试剂盒
US20200088748A1 (en) * 2016-12-08 2020-03-19 Dana-Farber Cancer Institute, Inc. Metabolic profiling of fixed samples
CN107158388B (zh) * 2017-07-11 2021-03-23 上海市第一人民医院 MIIP pS303阻断剂在制备抗肿瘤药物中的应用
ES2917629T3 (es) 2018-01-22 2022-07-11 Liquid Biopsy Res Llc Métodos para la detección del cáncer de colon y monitorización del tratamiento
AU2019252672B2 (en) 2018-04-12 2025-08-14 Board Of Regents, The University Of Texas System Biomarker for detecting cancer
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
CN111321220A (zh) * 2018-12-14 2020-06-23 中国医学科学院肿瘤医院 用于检测直肠癌放化疗敏感性的组合物、微阵列和计算机系统
CN110079607B (zh) * 2019-04-04 2022-08-02 陕西师范大学 一种引物组、检测血液样品种属的方法及应用
EP3976820A1 (en) 2019-05-30 2022-04-06 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
WO2021247543A2 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Nucleic acid library methods
CN116249785A (zh) 2020-06-02 2023-06-09 10X基因组学有限公司 用于抗原-受体的空间转录组学
EP4162074B1 (en) 2020-06-08 2024-04-24 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
CN115997123A (zh) * 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
CN111951883A (zh) * 2020-08-04 2020-11-17 广东省第二人民医院(广东省卫生应急医院) 一种特征mRNA表达谱组合及结肠癌早期预测方法
CN115786518A (zh) * 2022-11-29 2023-03-14 广东医科大学附属医院 嗅素结构域家族蛋白4(olfm4)在结肠癌检测产品中的应用
WO2024206495A2 (en) * 2023-03-27 2024-10-03 Immunis.Ai, Inc. Active surveillance and risk stratification for prostate cancer
CN119372311A (zh) * 2024-09-30 2025-01-28 东南大学 基于成纤维细胞相关基因的结肠癌预后和治疗抵抗预测模型的构建方法和应用
CN120009551B (zh) * 2025-02-27 2025-08-15 西南医科大学 剪接因子wbp11及其抑制剂的用途、预防或治疗结直肠癌的药物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU575586B2 (en) 1983-09-02 1988-08-04 Syngene, Inc. Oligonucleotide synthesis employing primer with oxidzable substituents in system
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
WO1990001069A1 (en) 1988-07-20 1990-02-08 Segev Diagnostics, Inc. Process for amplifying and detecting nucleic acid sequences
US5219727A (en) 1989-08-21 1993-06-15 Hoffmann-Laroche Inc. Quantitation of nucleic acids using the polymerase chain reaction
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
DE69503126T2 (de) 1994-05-05 1998-11-12 Beckman Instruments Inc Repetitive oligonukleotide matrix
DE69524105T2 (de) 1994-07-15 2002-07-18 Organon Teknika B.V., Boxtel Verwendung von rna-polymerase zur verbesserung von nukeinsaeure-amplifikationsverfahren
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
CA2255774C (en) 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5985567A (en) 1997-08-15 1999-11-16 Beckman Coulter, Inc. Hybridization detection by pretreating bound single-stranded probes
US6013789A (en) 1998-02-20 2000-01-11 Beckman Coulter, Inc. Covalent attachment of biomolecules to derivatized polypropylene supports
AU2001252945A1 (en) 2000-03-24 2001-10-08 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
US20070166704A1 (en) 2002-01-18 2007-07-19 Fei Huang Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
US20040146921A1 (en) 2003-01-24 2004-07-29 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2005054508A2 (en) 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
WO2005068664A2 (en) 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
WO2005083128A2 (en) 2004-02-25 2005-09-09 University Of South Florida Methods for predicting cancer outcome and gene signatures for use therein
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
EP1774044A4 (en) 2004-06-03 2009-06-10 Univ Johns Hopkins METHODS OF SCREENING FOR CELL PROLIFERATION OR NEOPLASTIC DISORDERS
AU2005300688B2 (en) 2004-11-03 2012-02-02 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
CN101370946B (zh) * 2005-10-21 2011-07-20 基因信息股份有限公司 用于使生物标志产物水平与疾病相关联的方法和装置
DK1974058T3 (da) * 2006-01-11 2014-09-01 Genomic Health Inc Genekspressionsmarkører til prognosticering af kolorektal cancer
US20100009905A1 (en) * 2006-03-24 2010-01-14 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Colon Cancer
WO2008093323A2 (en) 2007-01-29 2008-08-07 Compugen Ltd. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
BRPI0912046B1 (pt) * 2008-05-27 2020-11-24 Agilent Technologies, Inc Composições de hibridizaqao e seu uso, bem como metodo de hibridizaqao de sequencias de acido nucleico
WO2010060055A1 (en) 2008-11-21 2010-05-27 Duke University Predicting cancer risk and treatment success

Also Published As

Publication number Publication date
AU2012209074A1 (en) 2013-07-11
CN103403543A (zh) 2013-11-20
WO2012103250A3 (en) 2012-10-11
US10196691B2 (en) 2019-02-05
NZ612471A (en) 2015-11-27
JP2014509189A (ja) 2014-04-17
WO2012103250A2 (en) 2012-08-02
SG192108A1 (en) 2013-08-30
IL227643A0 (en) 2013-09-30
BR112013018924A2 (pt) 2018-05-08
EP2668296A4 (en) 2015-09-02
EP2668296B1 (en) 2018-08-15
EP2668296A2 (en) 2013-12-04
CN103403543B9 (zh) 2017-05-17
KR20140006898A (ko) 2014-01-16
EA201391074A1 (ru) 2013-12-30
MX2013008367A (es) 2013-08-12
US20140094379A1 (en) 2014-04-03
ZA201305024B (en) 2014-03-26
CN103403543B (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
US10196691B2 (en) Colon cancer gene expression signatures and methods of use
AU2022203428A1 (en) Gene expression panel for prognosis of prostate cancer recurrence
JP4938672B2 (ja) p53の状態と遺伝子発現プロファイルとの関連性に基づき、癌を分類し、予後を予測し、そして診断する方法、システム、およびアレイ
JP6404304B2 (ja) メラノーマ癌の予後予測
US20080058432A1 (en) Molecular assay to predict recurrence of Duke's B colon cancer
CA2859663A1 (en) Identification of multigene biomarkers
CN104603292A (zh) 用于提供前列腺癌的临床评估的方法、试剂盒和组合物
WO2014071279A2 (en) Gene fusions and alternatively spliced junctions associated with breast cancer
EP2524051A2 (en) Diagnostic gene expression platform
EP3472361A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
KR20180009762A (ko) 폐암을 진단하거나 검출하기 위한 방법 및 조성물
CN101960022A (zh) Ⅱ期和ⅲ期结肠癌的分子分期和预后
US20250137066A1 (en) Compostions and methods for diagnosing lung cancers using gene expression profiles
WO2013109613A1 (en) Gene signature is associated with early stage rectal cancer recurrence
EP1355151A2 (en) Assessing colorectal cancer
EP1683862B1 (en) Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis
EP1355149A2 (en) Assessing colorectal cancer
NZ612471B2 (en) Colon cancer gene expression signatures and methods of use
CN110079601A (zh) 放射性相关疾病诊疗标志物及其应用
HK1231515B (en) Gene expression panel for prognosis of prostate cancer recurrence
HK1191675A (en) Prognostic signature for colorectal cancer recurrence

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180125